Form 8-K - Current report:
SEC Accession No. 0001549595-25-000094
Filing Date
2025-07-09
Accepted
2025-07-09 16:02:39
Documents
13
Period of Report
2025-07-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrix-20250709.htm   iXBRL 8-K 27881
2 EX-99.1 nrix-20250709xexx991.htm EX-99.1 95305
  Complete submission text file 0001549595-25-000094.txt   263246

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20250709.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20250709_lab.xml EX-101.LAB 24350
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20250709_pre.xml EX-101.PRE 14116
15 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20250709_htm.xml XML 3016
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 251113612
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)